… Small cell lung cancer (SCLC) remains a fatal disease due to limited therapeutic options. …
similar to the accomplishments of the last decade with non-small cell lung cancer (NSCLC). …

… Until recently, nivolumab was the only ICI validated for advanced non-small-cell lung
cancer (NSCLC) in a second-line treatment setting. Results from recent phase II and phase III …

… The neurologic syndromes are usually progressive and run their own course independently
of the cancer and outcomes of cancer therapy. The endocrine syndromes related to peptide …

… to therapy, alterations in lineage plasticity and cell fate … from diverse cell types (including
from lung adenocarcinoma cells) … initiate in neuroendocrine lung epithelial cells, observations …

… Lung cancer is the most common cause of cancer-related death. Small cell lung cancer (SCLC)
currently comprises about 14% of all lung cancer cases diagnosed in the United States [1…

… are used to distinguish squamous cell carcinoma from … of lung cancer has become more
important in the past few years owing to the availability of an increasing number of therapeutic …

… ICBs are poised to move to earlier stages of lung cancer therapy, in an attempt to improve
survival after surgery or radiotherapy, in which the goal is curative. A randomized trial of …

… Lung cancer is often diagnosed at an advanced stage, rendering the disease intractable.
Lung cancer can be broadly categorized into non-small-cell … stage small-cell lung cancer (ED …

… Stephens, RJ Prophylactic cranial irradiation is indicated following complete response to
induction therapy in small cell lung cancer: results of a multicentre randomised trial. United …

Currently, chemotherapy remains the standard treatment for first- and second-line management
of small cell lung cancer (SCLC). Immunotherapy has made progress in the treatment of …